Physician profile
Bryan Noel Doherty
NPI 1497123384
$957.15
in general payments reported to CMS, 2019-2025
15 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2022: $43.03 · 2023: $86.17 · 2024: $439 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $171.39 | 2024 | Apollo Esg Nxt System, Resolution 360 Clip, Cre Pro |
| Abbvie INC. | $159.84 | 2024-2025 | |
| Gilead Sciences, INC. | $122.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.05 | 2019-2025 | Xifaxan, Trulance |
| Olympus Corporation of The Americas | $71.41 | 2019 | |
| Pfizer INC. | $67.35 | 2023-2025 | |
| Olympus America INC. | $66.69 | 2022-2024 | Disposable Biopsy Forceps, Endoclot Phs |
| Braintree Laboratories, INC. | $47.86 | 2022-2024 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $38.50 | 2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $31.18 | 2024 | Voquezna |
| Medtronic, INC. | $30.91 | 2025 | Gi Genius |
| Genzyme Corporation | $23.10 | 2023 | |
| Erbe USA INC | $15.89 | 2024 | |
| Aimmune Therapeutics, INC. | $15.55 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,523.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.